Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure

Circulation
S S GottliebM Packer

Abstract

Many of the newer antiarrhythmic agents are said to cause minimal myocardial depression, but their hemodynamic effects have not been invasively evaluated and compared in patients with severe chronic heart failure. In a randomized, crossover study, the hemodynamic responses to single oral doses of procainamide (750 mg), tocainide (600 mg), and encainide (50 mg) given to 21 patients with severe chronic heart failure were compared. Cardiac performance decreased with all three drugs, but the magnitude of deterioration differed among the three agents. Stroke volume index decreased with procainamide (-5 +/- 1 ml/m2, p less than 0.001), tocainide (-7 +/- 1 ml/m2, p less than 0.001), and encainide (-8 +/- 1 ml/m2, p less than 0.001), but the decline was significantly greater with encainide than with procainamide (p less than 0.05). Similarly, left ventricular filling pressure increased with tocainide and encainide (+4 +/- 1 and +5 +/- 2 mm Hg, respectively; both p less than 0.05), but not with procainamide; the increase was significantly greater with tocainide and encainide than with procainamide (p less than 0.001). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in six patients with encai...Continue Reading

References

Feb 1, 1979·Journal of Clinical Pharmacology·M SchwartzE Smith
Aug 1, 1976·The American Journal of Medicine·J R BurtonP W Armstrong
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Apr 1, 1989·Annals of Internal Medicine·S S GottliebM Packer
Jan 1, 1986·Journal of the American College of Cardiology·J MorganrothD M Salerno
Aug 29, 1986·The American Journal of Cardiology·A W GomollM J Antonaccio
Aug 1, 1987·Journal of the American College of Cardiology·B Surawicz
Nov 1, 1972·American Heart Journal·K E HammermeisterJ R Warbasse
Dec 1, 1973·The American Journal of Cardiology·P CôteJ S Schroeder
Jul 1, 1974·The American Journal of Cardiology·D J ColtartD C Harrison
Mar 1, 1971·JAMA : the Journal of the American Medical Association·J Koch-Weser, S W Klein
Feb 1, 1969·The American Journal of Cardiology·R A O'RourkeE Rapaport
Nov 1, 1965·The American Journal of Cardiology·W G Austen, J M Moran
Apr 1, 1982·Clinical Pharmacology and Therapeutics·M H CrawfordK W Amon
Jan 1, 1983·Journal of Cardiovascular Pharmacology·M B RenardM Englert
May 1, 1983·Clinical Pharmacology and Therapeutics·A J AtkinsonM J Nevin
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Dec 3, 1981·European Journal of Pharmacology·D L Brutsaert
Apr 1, 1982·The American Journal of Cardiology·P J Podrid, B Lown
Oct 1, 1980·European Journal of Clinical Pharmacology·P GelerisJ J Lima

❮ Previous
Next ❯

Citations

Jul 1, 1990·Clinical Cardiology·D Katritsis, A J Camm
Nov 1, 1991·Journal of Clinical Pharmacology·H FruminN Kerin
Dec 1, 1992·Journal of the American College of Cardiology·C Chelimsky-FallickH Laks
Mar 1, 1994·Journal of the American College of Cardiology·S S GottliebM R Gold
Aug 29, 1996·The American Journal of Cardiology·H L Greene
Aug 15, 1997·The American Journal of Cardiology·B S StamblerJ T VanderLugt
Apr 8, 1999·Journal of the American College of Cardiology·J FeenstraB H Stricker
Jun 15, 1999·Journal of Cardiovascular Pharmacology·I KamekuraT Ito
Jan 13, 2004·Journal of Cardiovascular Pharmacology·Maria SzekeresAkos Koller
Nov 1, 1990·Pacing and Clinical Electrophysiology : PACE·S S Gottlieb
Apr 1, 1992·Pacing and Clinical Electrophysiology : PACE·B S StamblerK A Ellenbogen
Feb 1, 1993·Pacing and Clinical Electrophysiology : PACE·D L WareD S Echt
Nov 30, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·T Jared Bunch, Jeffrey L Anderson
Jul 1, 1993·American Heart Journal·N TwidaleR J McRitchie
May 29, 1991·The American Journal of Medicine·L Storstein
Mar 7, 2006·Progress in Cardiovascular Diseases·E Kevin Heist, Jeremy N Ruskin
May 30, 2001·The American Journal of Cardiology·M F RousseauH Pouleur
Oct 1, 1993·Postgraduate Medicine·J B Conti, A B Curtis
Mar 1, 1991·DICP : the Annals of Pharmacotherapy·M A MaleskerM H Sketch
Aug 5, 2011·Clinical Pharmacology and Therapeutics·B CharbitC Funck-Brentano
Jul 5, 2021·Heart Failure Reviews·Grigorios TsigkasPeriklis Davlouros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.